June 20, 2021
Business News

Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy

WEST CHESTER, Pa.–()–Molecular Targeting Technologies, Inc. (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA (99mTc-Duramycin), in patients with advanced colorectal cancer (CRC)*.

Colorectal cancer is the third most commonly diagnosed malignancy in the world and the second leading cause of cancer death in the United States. While a range of novel active agents has improved the prognosis of patients with colorectal cancer, 50% of advanced colorectal cancer patients die from metastatic…

Click here to view the original article.

Related Posts

You might also like ...

Prime Day Smart Home Deals 2021: Top Early Security Camera, Smart Thermostat, Home Security & More Sales Rated by Spending Lab
Best Prime Day Toys Deals 2021: Early Board Games, Baby Toys, Osmo, LeapFrog & More Sales Rounded Up by Consumer Articles
AON Splash Image
Prime Day Smart TV Deals (2021): Early Samsung, LG, Sony, TCL, Sharp, Vizio & More Sales Identified by Deal Tomato